Literature DB >> 29618154

Low Plasma ADAMTS13 Activity Is Associated with Coagulopathy, Endothelial Cell Damage and Mortality after Severe Paediatric Trauma.

Robert T Russell1, Jenny K McDaniel2, Wenjing Cao2, Michelle Shroyer1, Brant M Wagener3, X Long Zheng2, Jean-François Pittet3.   

Abstract

Decrease of plasma activity of ADAMTS13, a metalloenzyme that cleaves von Willebrand factor (VWF) and prevents adhesion and aggregation of platelets, has been reported early after onset of systemic inflammation resulting from infections and after severe trauma. Here, we determined whether trauma-induced systemic (sterile) inflammation would be associated with a reduction of plasma ADAMTS13 activity in paediatric patients and its association with disease severity and outcome. Paediatric patients (n = 106) with severe trauma at a level 1 paediatric trauma centre between 2014 and 2016 were prospectively enrolled. Blood samples were collected upon arrival and at 24 hours and analysed for plasma levels of ADAMTS13 activity, VWF antigen, collagen binding activity, human neutrophil peptides (HNP) 1-3, coagulation abnormalities, endothelial glycocalyx damage and clinical outcome. Plasma samples were also collected for similar measurements from 52 healthy paediatric controls who underwent elective minor surgery. The median age of patients was 9 years with 81% sustaining blunt trauma. The median injury severity score was 22 and the mortality rate was 11%. Plasma levels of ADAMTS13 activity were significantly lower and plasma levels of VWF antigen and HNP 1-3 proteins were significantly higher for paediatric trauma patients on admission and at 24 hours when compared with controls. Finally, the lowest plasma ADAMTS13 activity was found in patients who died from their injuries. We conclude that relative plasma deficiency of ADAMTS13 activity may be associated with more severe traumatic injury, significant endothelial glycocalyx damage, coagulation abnormalities and mortality after severe trauma in paediatric patients. Schattauer GmbH Stuttgart.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29618154      PMCID: PMC6433136          DOI: 10.1055/s-0038-1636528

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  50 in total

1.  Defensins and host defense.

Authors:  T Ganz
Journal:  Science       Date:  1999-10-15       Impact factor: 47.728

Review 2.  The endothelium in sepsis: source of and a target for inflammation.

Authors:  C E Hack; S Zeerleder
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

3.  Platelet-derived VWF-cleaving metalloprotease ADAMTS-13.

Authors:  L Liu; H Choi; A Bernardo; A L Bergeron; L Nolasco; C Ruan; J L Moake; J-F Dong
Journal:  J Thromb Haemost       Date:  2005-09-13       Impact factor: 5.824

4.  Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13.

Authors:  Arnaud Bonnefoy; Kim Daenens; Hendrik B Feys; Rita De Vos; Petra Vandervoort; Jos Vermylen; Jack Lawler; Marc F Hoylaerts
Journal:  Blood       Date:  2005-10-04       Impact factor: 22.113

5.  The injured child is resistant to multiple organ failure: a different inflammatory response?

Authors:  Casey M Calkins; Denis D Bensard; Ernest E Moore; Robert C McIntyre; Christopher C Silliman; Walter Biffl; Alden H Harken; David A Partrick; Patrick J Offner
Journal:  J Trauma       Date:  2002-12

6.  FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay.

Authors:  Koichi Kokame; Yuko Nobe; Yoshihiro Kokubo; Akira Okayama; Toshiyuki Miyata
Journal:  Br J Haematol       Date:  2005-04       Impact factor: 6.998

7.  Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts.

Authors:  Dezhi Shang; X Wu Zheng; Masami Niiya; X Long Zheng
Journal:  Blood       Date:  2006-04-04       Impact factor: 22.113

8.  Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease.

Authors:  Pier Mannuccio Mannucci; Cristina Capoferri; Maria Teresa Canciani
Journal:  Br J Haematol       Date:  2004-07       Impact factor: 6.998

9.  Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow.

Authors:  Aubrey Bernardo; Chalmette Ball; Leticia Nolasco; Joel F Moake; Jing-fei Dong
Journal:  Blood       Date:  2004-03-16       Impact factor: 22.113

10.  Control of von Willebrand factor multimer size by thrombospondin-1.

Authors:  L Xie; C N Chesterman; P J Hogg
Journal:  J Exp Med       Date:  2001-06-18       Impact factor: 14.307

View more
  10 in total

1.  Plasma and rhADAMTS13 reduce trauma-induced organ failure by restoring the ADAMTS13-VWF axis.

Authors:  Derek J B Kleinveld; Derek D G Simons; Charlotte Dekimpe; Shannen J Deconinck; Pieter H Sloos; M Adrie W Maas; Jesper Kers; Joshua Muia; Karim Brohi; Jan Voorberg; Karen Vanhoorelbeke; Markus W Hollmann; Nicole P Juffermans
Journal:  Blood Adv       Date:  2021-09-14

2.  Von Willebrand factor as a thrombotic and inflammatory mediator in critical illness.

Authors:  William E Plautz; Zachary A Matthay; Marian A Rollins-Raval; Jay S Raval; Lucy Z Kornblith; Matthew D Neal
Journal:  Transfusion       Date:  2020-06-01       Impact factor: 3.157

3.  Plasma Level of von Willebrand Factor Propeptide at Diagnosis: A Marker of Subsequent Renal Dysfunction in Autoimmune Rheumatic Diseases.

Authors:  Noritaka Yada; Kiyomi Yoshimoto; Hiromasa Kawashima; Ryo Yoneima; Nobushiro Nishimura; Yoshiaki Tai; Emiko Tsushima; Makiko Miyamoto; Shiro Ono; Masanori Matsumoto; Takashi Fujimoto; Kenji Nishio
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

4.  ADAMTS13 activity decreases in the early phase of trauma associated with coagulopathy and systemic inflammation: a prospective observational study.

Authors:  Hironori Matsumoto; Jun Takeba; Kensuke Umakoshi; Satoshi Kikuchi; Muneaki Ohshita; Suguru Annen; Naoki Moriyama; Yuki Nakabayashi; Norio Sato; Mayuki Aibiki
Journal:  Thromb J       Date:  2021-03-12

5.  Quantification of von Willebrand factor and ADAMTS-13 after traumatic injury: a pilot study.

Authors:  Taleen A MacArthur; Julie Goswami; Laurie Moon Tasson; Alexander Tischer; Kent R Bailey; Grant M Spears; Jing-Fei Dong; Matthew Auton; Rosemary Kozar; Myung S Park
Journal:  Trauma Surg Acute Care Open       Date:  2021-04-05

6.  Low ADAMTS-13 predicts adverse outcomes in hospitalized patients with suspected heparin-induced thrombocytopenia.

Authors:  Meng Chan; Xinyang Zhao; X Long Zheng
Journal:  Res Pract Thromb Haemost       Date:  2021-09-16

Review 7.  Platelet dysfunction after trauma: From mechanisms to targeted treatment.

Authors:  Pieter H Sloos; Paul Vulliamy; Cornelis van 't Veer; Anirban Sen Gupta; Matthew D Neal; Karim Brohi; Nicole P Juffermans; Derek J B Kleinveld
Journal:  Transfusion       Date:  2022-06-24       Impact factor: 3.337

Review 8.  Endothelial glycocalyx in acute care surgery - what anaesthesiologists need to know for clinical practice.

Authors:  David Astapenko; Jan Benes; Jiri Pouska; Christian Lehmann; Sufia Islam; Vladimir Cerny
Journal:  BMC Anesthesiol       Date:  2019-12-20       Impact factor: 2.217

9.  Acrolein Induces Systemic Coagulopathy via Autophagy-dependent Secretion of von Willebrand Factor in Mice after Traumatic Brain Injury.

Authors:  Wenxing Cui; Xun Wu; Dayun Feng; Jianing Luo; Yingwu Shi; Wei Guo; Haixiao Liu; Qiang Wang; Liang Wang; Shunnan Ge; Yan Qu
Journal:  Neurosci Bull       Date:  2021-05-03       Impact factor: 5.203

10.  Coagulation disorders in patients with severe hemophagocytic lymphohistiocytosis.

Authors:  Sandrine Valade; Bérangère S Joly; Agnès Veyradier; Jehane Fadlallah; Lara Zafrani; Virginie Lemiale; Amélie Launois; Alain Stepanian; Lionel Galicier; Claire Fieschi; Adrien Mirouse; Jean Jacques Tudesq; Anne-Claire Lepretre; Elie Azoulay; Michael Darmon; Eric Mariotte
Journal:  PLoS One       Date:  2021-08-03       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.